- TheStreet.com•6 hours ago
AstraZeneca (AZN) stock is increasing this afternoon after the company reported better-than-expected results before today's market open.
- Reuters•11 hours ago
AstraZeneca's chief executive believes a rival could spot the growing value of its drug pipeline but declined to say if the group was likely to be a takeover target once more, two years after seeing off a bid from Pfizer. This time speculation has moved to the idea of a possible offer from Swiss-based Novartis, which would increase its cancer drug operations significantly by acquiring its smaller British rival. Citi analyst Andrew Baum suggested in a note this week that AstraZeneca's biotech expertise and advanced immunotherapy cancer pipeline made it an attractive target for the Basel-based group.
After hours: 82.090.01 (0.01%) as of 5:16 PM EDT
|Bid||82.07 x 400|
|Ask||82.08 x 1100|
|52wk Range||69.90 - 104.75|
|Day's Range||81.57 - 82.58|
|Avg Vol (3m)||1,809,768|
As of 4:02 PM EDT. Market closed.